Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLEG GLIGICH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215224126
CMS profile
2793387
Location
BROOKSVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$6,740.54

244 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLEG GLIGICH

NPI 1215224126 · CMS profile ID 2793387

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BROOKSVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215224126?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLEG GLIGICH, NPI 1215224126, CMS profile ID 2793387. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215224126?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). OLEG GLIGICH, NPI 1215224126, CMS profile ID 2793387. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215224126?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
OLEG GLIGICH, NPI 1215224126, CMS profile ID 2793387, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1215224126?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

244 matching records · $6,740.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 244 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 244.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $21.3307/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783708111 CMS
Eisai Inc. $19.9007/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817973171 CMS
Daiichi Sankyo Inc. $24.3607/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836307831 CMS
Janssen Biotech, Inc. $2.4207/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995731 CMS
Janssen Pharmaceuticals, Inc $13.7807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995779 CMS
Celgene Corporation $21.5207/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783708113 CMS
Kyowa Kirin, Inc. $16.9807/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852985229 CMS
AstraZeneca Pharmaceuticals LP $23.0207/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829470597 CMS
ARRAY BIOPHARMA INC $22.7607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833186577 CMS
Incyte Corporation $22.8407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835567887 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.1507/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789050963 CMS
Ipsen Biopharmaceuticals, Inc $22.1907/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841911987 CMS
Janssen Biotech, Inc. $2.0707/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995745 CMS
Janssen Biotech, Inc. $19.3007/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995747 CMS
MorphoSys, US Inc. $18.9406/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854736619 CMS
Amgen Inc. $17.6606/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826405029 CMS
EMD Serono, Inc. $9.8006/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849200121 CMS
EMD Serono, Inc. $2.7306/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849200149 CMS
EMD Serono, Inc. $14.1906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849194985 CMS
GENZYME CORPORATION $18.4206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843666973 CMS
AstraZeneca Pharmaceuticals LP $19.1106/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829606465 CMS
Genentech USA, Inc. $16.5506/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835959623 CMS
Myriad Genetic Laboratories, Inc. $15.5806/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834549619 CMS
Seagen Inc. $15.5906/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832196111 CMS
Celgene Corporation $13.8406/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783708109 CMS
Janssen Biotech, Inc. $19.3506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995761 CMS
Merck Sharp & Dohme Corporation $12.2906/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848336593 CMS
Genentech USA, Inc. $18.4606/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835959637 CMS
AbbVie Inc. $17.9406/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794608739 CMS
Pharmacyclics LLC, An AbbVie Company $19.8606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781010567 CMS
Amgen Inc. $12.2206/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825667875 CMS
Amgen Inc. $17.0906/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826405025 CMS
JAZZ PHARMACEUTICALS INC. $12.8806/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845594397 CMS
PFIZER INC. $14.7705/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832710961 CMS
E.R. Squibb & Sons, L.L.C. $19.3805/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783563073 CMS
PFIZER INC. $18.7605/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832635957 CMS
Janssen Biotech, Inc. $17.1205/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995743 CMS
EMD Serono, Inc. $3.2505/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849194897 CMS
EMD Serono, Inc. $13.1505/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849194947 CMS
GlaxoSmithKline, LLC. $11.5505/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801659813 CMS
Seagen Inc. $119.3105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832196115 CMS
Amgen Inc. $12.6305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825667871 CMS
Incyte Corporation $60.9905/18/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835567863 CMS
Incyte Corporation $14.6805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835567879 CMS
AstraZeneca Pharmaceuticals LP $22.9205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830035961 CMS
Janssen Pharmaceuticals, Inc $10.4005/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787995773 CMS
Epizyme, Inc., $99.9905/13/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832339807 CMS
AbbVie Inc. $19.9105/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794608735 CMS
EMD Serono, Inc. $14.2005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849190544 CMS
Incyte Corporation $16.6105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835567871 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,316.91 77
PY2020 $4,482.70 159
PY2021 $6,740.54 244
PY2022 $6,348.98 249
PY2023 $8,051.62 215
PY2024 $6,520.41 226
PY2025 $14,554.90 221

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $331,278.47 57
PY2024 Principal investigator $456,500.28 62
PY2023 Principal investigator $54,159.10 47
PY2022 Principal investigator $89,987.72 14
PY2021 Principal investigator $55,387.78 37
PY2020 Principal investigator $14,407.14 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $101,232.35 12/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow No dispute reported 06/30/2026 1232924248
Principal investigator 1 Genentech, Inc. $4,860.00 12/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550910
Principal investigator 1 Genentech, Inc. $1,287.00 12/04/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550906
Principal investigator 1 Genentech, Inc. $7,466.00 11/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Early Stage to Locally Advanced Non Small Cell Lung Cancer platform stage 3 unresectable No dispute reported 06/30/2026 1211550726
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,600.00 11/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185552279
Principal investigator 1 Janssen Research & Development, LLC $1,800.00 10/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391068
Principal investigator 1 Genentech, Inc. $7,186.00 10/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550894
Principal investigator 1 Genentech, Inc. $3,198.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550852
Principal investigator 1 Genentech, Inc. $115.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550859
Principal investigator 1 Genentech, Inc. $144.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550867
Principal investigator 1 Genentech, Inc. $323.00 09/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550890
Principal investigator 1 Genentech, Inc. $3,645.00 08/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550856
Principal investigator 1 BeOne Medicines USA, Inc. $1,745.97 07/29/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies No dispute reported 06/30/2026 1190328431
Principal investigator 1 BeOne Medicines USA, Inc. $1,562.50 07/29/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies No dispute reported 06/30/2026 1190332183
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 07/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175390882
Principal investigator 1 Genentech, Inc. $230.00 07/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550880
Principal investigator 1 Genentech, Inc. $228.00 07/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550887
Principal investigator 1 Genentech, Inc. $96.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550864
Principal investigator 1 Genentech, Inc. $676.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550872
Principal investigator 1 Genentech, Inc. $323.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550876
Principal investigator 1 Genentech, Inc. $115.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550884
Principal investigator 1 Janssen Research & Development, LLC $3,770.00 07/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175391062
Principal investigator 1 Genentech, Inc. $1,215.00 06/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550807
Principal investigator 1 Genentech, Inc. $7,186.00 06/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550826
Principal investigator 1 Genentech, Inc. $3,750.00 05/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550815
Principal investigator 1 Janssen Research & Development, LLC $625.00 05/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175390851
Principal investigator 1 Genentech, Inc. $2,430.00 05/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550823
Principal investigator 1 Genentech, Inc. $625.00 04/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Early Stage to Locally Advanced Non Small Cell Lung Cancer platform stage 3 unresectable No dispute reported 06/30/2026 1211550720
Principal investigator 1 Genentech, Inc. $6,486.00 04/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550830
Principal investigator 1 Genentech, Inc. $115.00 03/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550758
Principal investigator 1 Genentech, Inc. $256.00 03/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550762
Principal investigator 1 Genentech, Inc. $48.00 03/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550766
Principal investigator 1 BeOne Medicines USA, Inc. $250.00 03/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies No dispute reported 06/30/2026 1190338629
Principal investigator 1 BeOne Medicines USA, Inc. $900.00 03/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies No dispute reported 06/30/2026 1190338632
Principal investigator 1 AstraZeneca Pharmaceuticals LP $67,404.30 03/12/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185552281
Principal investigator 1 Genentech, Inc. $323.00 03/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550775
Principal investigator 1 Genentech, Inc. $128.00 03/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550778
Principal investigator 1 Janssen Research & Development, LLC $531.60 03/10/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. No dispute reported 06/30/2026 1175390924
Principal investigator 1 Genentech, Inc. $1,215.00 03/04/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550770
Principal investigator 1 Daiichi Sankyo Inc. $1,250.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-0001-CIS-MA No dispute reported 06/30/2026 1223349072
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-0001-CIS-MA No dispute reported 06/30/2026 1223349074
Principal investigator 1 Daiichi Sankyo Inc. $625.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-0001-CIS-MA No dispute reported 06/30/2026 1223349076
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-0001-CIS-MA No dispute reported 06/30/2026 1223349078
Principal investigator 1 Daiichi Sankyo Inc. $375.00 03/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
DS8201-0001-CIS-MA No dispute reported 06/30/2026 1223349080
Principal investigator 1 Genentech, Inc. $48.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550787
Principal investigator 1 Genentech, Inc. $60.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550791
Principal investigator 1 Genentech, Inc. $55.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550795
Principal investigator 1 Genentech, Inc. $323.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550803
Principal investigator 1 Genentech, Inc. $128.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550819
Principal investigator 1 Genentech, Inc. $256.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550835
Principal investigator 1 Genentech, Inc. $159.00 02/18/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550840
Principal investigator 1 Genentech, Inc. $6,075.00 02/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550784
Principal investigator 1 Genentech, Inc. $7,543.00 02/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550799
Principal investigator 1 PFIZER INC. $27,342.75 02/05/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228708924
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,450.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1236000512
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,445.00 01/22/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185552283
Principal investigator 1 Genentech, Inc. $453.00 01/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Medical Center Of Florid
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211550811